UBS Group AG Sells 105,966 Shares of Compass Pathways PLC Sponsored ADR $CMPS

UBS Group AG lowered its position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 4.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,038,444 shares of the company’s stock after selling 105,966 shares during the quarter. UBS Group AG owned about 2.12% of Compass Pathways worth $14,065,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Advisory Services Network LLC bought a new position in shares of Compass Pathways during the 3rd quarter worth approximately $41,000. BIT Capital GmbH bought a new position in shares of Compass Pathways during the 3rd quarter worth approximately $54,000. Raymond James Financial Inc. boosted its holdings in shares of Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after buying an additional 6,228 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new position in shares of Compass Pathways during the 4th quarter worth approximately $104,000. Finally, CWM LLC boosted its holdings in shares of Compass Pathways by 19.2% during the 3rd quarter. CWM LLC now owns 15,650 shares of the company’s stock worth $90,000 after buying an additional 2,525 shares in the last quarter. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

Shares of NASDAQ:CMPS opened at $10.96 on Thursday. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. Compass Pathways PLC Sponsored ADR has a twelve month low of $2.25 and a twelve month high of $11.08. The stock’s 50 day moving average is $7.09 and its 200-day moving average is $6.69. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -3.55 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Sell-side analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.83 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Morgan Stanley cut their price target on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a report on Wednesday, March 25th. B. Riley Financial assumed coverage on Compass Pathways in a report on Friday, April 24th. They set a “buy” rating and a $17.00 price target on the stock. UBS Group set a $18.00 price target on Compass Pathways in a report on Thursday, May 7th. Royal Bank Of Canada increased their price target on Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Finally, HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Compass Pathways in a report on Tuesday, April 28th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Compass Pathways currently has a consensus rating of “Moderate Buy” and an average target price of $20.55.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.